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Abstract: The onset of narcolepsy, an irreversible sleep disorder, has been associated with 2009
influenza pandemic (pH1N1) infections in China, and with ASO3-adjuvanted pH1N1 vaccinations
using Pandemrix in Europe. Intriguingly, however, the increased incidence was only observed
following vaccination with Pandemrix but not Arepanrix in Canada. In this study, the mutational
burden of actual vaccine lots of Pandemrix (n = 6) and Arepanrix (n = 5) sourced from Canada,
and Northern Europe were characterized by mass spectrometry. The four most abundant influenza
proteins across both vaccines were nucleoprotein NP, hemagglutinin HA, matrix protein M1, with the
exception that Pandemrix harbored a significantly increased proportion of neuraminidase NA (7.5%)
as compared to Arepanrix (2.6%). Most significantly, 17 motifs in HA, NP, and M1 harbored
mutations, which significantly differed in Pandemrix versus Arepanrix. Among these, a 6-fold higher
deamidation of HA146 (p.Asn146Asp) in Arepanrix was found relative to Pandemrix, while NP257
(p.Thr257Ala) and NP424 (p.Thr424Ile) were increased in Pandemrix. DQ0602 binding and tetramer
analysis with mutated epitopes were conducted in Pandemrix-vaccinated cases versus controls but
were unremarkable. Pandemrix harbored lower mutational burden than Arepanrix, indicating higher
similarity to wild-type 2009 pH1N1, which could explain differences in narcolepsy susceptibility
amongst the vaccines.
Keywords: narcolepsy; influenza vaccine; mass spectrometry; mutations
1. Introduction
Type 1 Narcolepsy (T1N) is a disabling disorder characterized by excessive daytime sleepiness,
irresistible daytime sleep attacks, and sudden episodes of loss of muscle tone following emotions such
as laughter, a symptom known as cataplexy [1]. Genetic and immunological studies have shown that
the disorder is autoimmune, and likely mediated by T cell attacks targeting hypocretin producing
neurons, a population of 20,000 neurons located in the posterior hypothalamus [2,3]. Hypocretins are
critical regulators of wakefulness and Rapid Eye Movement sleep (REM sleep), and lack of hypocretin
transmission is causal to the symptoms of the disorder [4,5].
Until recently, the rationale for an autoimmune basis for narcolepsy was based mainly on
epidemiological and genetic evidence. First, there is a uniquely strong association between narcolepsy
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and 6p21.3, a region of the genome, including the human leukocyte antigen HLA locus, more specifically,
97% of narcoleptic patients carry at least one copy of HLA DQB1*06:02 (DQ0602) across ethnicities,
an HLA class II allele found in 25% of the general population [6–8]. Additional weak effects
in HLA-A*11:01 [9] and an impact of DQB1*03:01 on the age of onset were also observed [10].
Genome-wide association studies have found that narcolepsy is associated with T-cell receptor loci
TRA & TRB, and immune genes such as CTSH, P2RY11, ZNF265, IFNAR1, and TNSF4 [10–12].
As all these loci are involved in immune regulation and other autoimmune diseases, an autoimmune
mediation of hypocretin cell death has long been proposed as the cause of narcolepsy. Of notable
interest is the fact the TCR loci associated with narcolepsy are modulators of TRAJ24 and TRBV4-2,
TCR segments only involved in 0.8% and 0.7% of the total TCR repertoire, respectively.
Narcolepsy studies have described environmental triggers in addition to the genetic susceptibilities;
specifically, while some studies have noted increased humoral (IgG) and cellular (IFNγ) responses to
streptococcus pyogenes infection [13,14] others have reported no differences in Chinese narcolepsy
patients [15]. Similarly, epidemiological studies have suggested increased frequency of strep infections
and flu-like illness in patients before developing narcolepsy [16]. Most recently, the data has most
strongly implicated influenza-A infection and vaccination. Following the 2009–2010 H1N1 “swine
flu” influenza pandemic infection in China, increased T1N onsets were observed [10]. In European
countries, a significant 4–16-fold increase in the risk of developing narcolepsy in children was observed
a few months following an aggressive pandemic H1N1 (pH1N1) flu vaccination campaign with the
vaccine Pandemrix [17–24]. In these cases, Pandemrix increased the incidence of narcolepsy by a
factor of 2–15, from around 1/150,000 to 1/15,000 cases per year in children. The risk was mostly
increased in younger children, but there was still a significant, albeit weaker effect in adults [20].
Similar increases in narcolepsy incidence were not observed in countries where other pandemic
vaccines, notably Arepanrix in Canada, were used, thereby elucidating the impression that Pandemrix
uniquely triggered narcolepsy [25].
Starting in May 2009 in response to the pandemic H1N1, vaccine manufacturers began to plan
the production of a specialized vaccine targeting the new strain for vaccination the following winter,
a concise timeline. The creation of vaccine strains involves growing strains derived from pathogenic
strains reassorted with PR8 (an old 1918-H1N1-like strain 08/35 from Puerto Rico) in eggs. The reassortant
strain is typically constructed by the New York Medical Center (NYMC), which is then distributed to
manufacturers for growing millions of doses in eggs in specialized factories. The NYMC H1N1-like
vaccine strains produced for the 2009–2010 swine flu campaign used A/H1N1/California/7/2009 as the
pathogenic strain, so that only Hemagglutinin (HA), Neuraminidase (NA), and polymerase PB1 are
derived from A/H1N1/California/7/2009, while other proteins are PR8 derived. In close succession,
NYMC-X-179A and NYMC X-181, a higher growth reassortant derived from X-179A were created,
with the former strain having been used more widely (X-181 was only used toward the end of
the season in some cases) [26]. Once distributed, vaccine manufacturers used their own patented
process to produce vaccines using X-179A and X-181. In egg-based vaccine production processes,
candidate vaccine viruses are grown in eggs per current FDA regulatory requirements. To do so,
X-179A is injected into fertilized hen’s eggs and incubated for several days to allow viruses to
replicate. The virus-containing allantoic fluid is then harvested from the eggs, viruses inactivated
(killed), and virus antigens purified, with the general goal of preferentially isolating viral surface
proteins HA and NA, which are most important for protective antibody responses sought with vaccine
administration [27,28].
Using this process, the manufacturer GlaxoSmithKline created Pandemrix and Arepanrix, both
AS03-adjuvanted vaccines; the AS03 adjuvant is an immunological agent added to the vaccine to
boost the immune system’s response to the target antigen while reducing the dosage of the viral
antigen (antigen sparing, a property that was desirable considering short time of production) [28].
Arepanrix was produced and used in Canada around the same time that Pandemrix was deployed in
Europe, but it did not sharply increase narcolepsy risk in Quebec [25,29]. This is notable as Arepanrix
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is almost identical to Pandemrix with a same adjuvant from the same geographic origin as well as
similar viral composition. However, different viral antigen purification techniques were used for either
vaccine—Fluarix for Pandemrix and Flulaval for Arepanrix [30]. Why Pandemrix in Europe and not
Arepanrix in Canada triggered narcolepsy cases is unknown. One possibility may be the differential
composition of the vaccine, notably due to the fact the viral antigens were extracted using different
manufacturing processes. Another possibility involves the presence of other factors differentiating
Canada and Europe at the time of vaccination. After all, it is essential to note that even with Pandemrix,
only 1/16,000 vaccinated children (or 1/4000 DQB0602 positive subjects) developed narcolepsy [19],
so that almost undoubtedly other environmental or stochastic factors are involved in addition to
vaccine trigger and genetic background. As Canadian and northern European populations are similar
in term of DQ0602 frequency (and other narcolepsy-associated genetic factors), a possibility could
be a differential immune history of both population regarding past flu or the fact that in Northern
Europe vaccination occurred shortly before or exactly when the pandemic H1N1 infection affected
the population. At the same time, in Canada the bulk of vaccination occurred immediately after the
pandemic flu started to change the population [23].
Our understanding of narcolepsy immunology changed significantly a few months ago, thanks to
two studies [31,32]. Latorre et al. used an ultrasensitive technique involving polyclonal expansion
and cloning of CD45RA−CD4+ memory T cells, found strong line reactivity to HCRT in all patients
versus no or limited responses in 12 DQ0602 controls, with significantly higher reactivity in T1N.
These authors found responses to seasonal influenza vaccine to be comparable in patients and controls,
concluding that flu antigen mimicry could not be detected [31]. On other hand, Luo et al. [32] screened
peptides derived from HCRT and flu strains including pH1N1 for DQ0602 binding and presence
of cognate tetramer-peptide specific CD4+ T cells in 35 T1N cases and 22 DQ0602 controls finding
higher reactivity to influenza pHA273–287 (pH1N1 specific) and C-amidated but not native version
of HCRT54–66 and HCRT86–97 sequences (two homologous sequences we denoted HCRTNH2) in T1N
when presented by DQ0602.
Relatively few studies have examined composition differences across flu vaccines such as
Pandemrix and Arepanrix. Comparative studies of antibody reactivity to Pandemrix and Arepanrix
antigens in both post-Pandemrix patients and control individuals found that post-Pandemrix-vaccinated
children had poorer antibody reactivity to Arepanrix, suggesting antigenic differences in antibody
determinants [33]. This could be important, although one would expect that differential susceptibility
would be more likely due to T cell response differences. High-resolution gel electrophoresis quantitation
and Mass Spectrometry (MS) identification analyses revealed higher amounts of structurally altered
viral nucleoprotein (NP) in Pandemrix versus Arepanrix, a finding that can also be noted in a 2-D gel
study by Jacob et al. [30]. These results suggest complex protein aggregate conformation differences
that could be relevant to differential activity of these vaccines, most notably in terms of antibody
response to NP. Jacob et al. [30] comparing single batches of Pandemrix and Arepanrix found that
viral proteins NP and NA as well as selected non-viral chicken proteins (PDCD6IP, TSPAN8, H-FABP,
HSP, and TUB) were more abundant in Pandemrix compared to Arepanrix. The study also found an
accumulation of a specific mutation in Arepanrix, 146N to D in Arepanrix, but as the batch studied had
only been synthesized in 2010 and had never been used for vaccination, it was hard to be sure if this
mutation had been present in earlier batches. Finally, Ahmed et al. [34] found an increased quantity of
cross-reactive antibodies to structurally altered NP epitope NP116I with an epitope from HCRTR2
protein in narcolepsy cases. Although the proportion of NP116I mutations in both Arepanrix and
Pandemrix was similar and, therefore, unlikely to be a causal effect, increased cross-reactive antibodies
between NP116I and HCRTR2 were not observed in other studies [35].
In the current study, we extended the previous findings from Jacob et al. [30] by characterizing the
protein content and mutational burden in 6 Pandemrix lots and 5 Arepanrix lots in relation to X-179A,
the influenza strain from which both vaccines were derived. Data shows batch diversity in mutation
burden that could be relevant to vaccine responses in some cases but not a distinct difference that could
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explain why Pandemrix was more associated with narcolepsy onsets than Arepanrix. Mutational drift
and low-level mutations are present in some vaccine batches (as occurring in wild type virus), and this
should be taken into consideration when studying the effects of these vaccines in the population.
2. Methods
2.1. Vaccines
Pandemrix doses used in the 2009 vaccination campaign were sourced from Sweden (3), France (1),
and additionally provided by GSK (2), while Arepanrix was sourced from Canada (4) and supplied by
GSK (1). All except for two lots were monovalent bulks (see Table 1). The vaccines were all derived
from the X-179A, a vaccine strain that built on the PR8 backbone and was populated with pH1N1
proteins (HA, NA and PB1) from the A/California/07/2009 strain. Pandemrix lots were prepared using
the Fluarix process in Dresden while the Arepanrix lots were processed using the Flulaval process in
Saint Foye as described [30]. All the vaccines were stored at +4C until assayed.
Table 1. Characteristics of Pandemrix and Arepanrix lots used in the Mass Spectrometry
(MS) characterization.
Vaccine Batch HA (ug/mL) Type Origin Viral Strain
Arepanrix AFLPA328AA 15 Vaccine Canada X179A
Arepanrix AFLPA359AA 15 Vaccine Canada X179A
Arepanrix AFLPA373BA 15 Vaccine Canada X179A
Arepanrix AFLPA319BB 15 Vaccine Canada X179A
Arepanrix SF1B0454CL 457 Bulk GSK X179A
Pandemrix AFLSA208A 15 Vaccine GSK X179A
Pandemrix AFLSA174AA 15 Vaccine France X179A
Pandemrix AFLSFDA280 139 Bulk GSK X179A
Pandemrix AFLSA167AB 15 Vaccine Sweden X179A
Pandemrix AFLSA097AA 15 Vaccine Sweden X179A
Pandemrix AFLSA096AA 15 Vaccine Sweden X179A
2.2. Mass Spectrometry (MS)
MS was performed on Trypsin/Lys-C (Promega Corporation, Madison, WI, USA), and Chymotrypsin
(Promega) digests of Pandemrix and Arepanrix samples (6.5 µg each) and detailed elsewhere [30].
Raw mass spectra of each vaccine digest (trypsin and chymotrypsin separately) were analyzed using a
combination of Preview and Byonic v.1.4 spectral analysis software (Protein Metrics Inc., Cupertino,
CA, USA). Complementary approaches were pursued. Spectrograms derived from each vaccine digest
were mapped to (i) a concatenated FASTA file containing the canonical proteomes for five influenza
viral strains: A/California/07/2009 (H1N1), NYMC X-181A (identical to NYMC X-181), NYMC X-179,
NYMC X-179A, and A/Puerto Rico/8/1934, and (ii) an in-silico mutant peptide library artificially
generated from X-179A that included all possible single amino acid substitutions in the five most
frequent flu proteins out of 14,894 unique proteins. Additional validation was done using typical
False Discovery Rate (FDR) by including common contaminants and sequence reverses in the FASTA
database for all searches. Data was qualified down to a 1% FDR level for proteins. Further fragments
that passed a threshold of log probability of 2 and were present four or more times in at least one
vaccine digest were considered for further analysis.
2.3. Statistical Analysis
After the MS vaccine, digest files were aligned to the reference library, and the mass spectra
were exported as CSV files from Byonic v.1.4 spectral analysis software (Protein Metrics, CA, USA)
and then processed through custom R and Python scripts. Using the Biopython library, the protein
sequences for the five reference flu proteins used in the MS processing were retrieved. For each
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reference flu protein, all corresponding peptides were extracted from the MS database and compared
to the reference protein sequence at each motif. From this comparison, the frequency of mutated
and wild-type amino acids relative to the X-179A derived viral strain was characterized at each
position in each protein in each vaccine batch. Then, mutation proportions were computed for each
position. After trypsin and chymotrypsin data from the same vaccine batch were merged, a two-tailed
Student’s t-test was used to determine significant mutation proportions between Pandemrix and
Arepanrix batches, thus pinpointing the specific mutations that significantly distinguished Arepanrix
and Pandemrix vaccines.
2.4. DQ0602 Binding
The in-vitro binding has been described in detail in Luo et al. [32,35] and is briefly described here,
Peptide competing binding assays were conducted by incubation of 25 nM DQ0602, 100 nM HLA-DM,
1 µM biotin-conjugated Epstein-Barr virus (EBV) epitope (Bio-EBV, Bio-GGGRALLARSHVERTTDE),
with 40 µM of the competitor peptide in reaction buffer (100 mM acetate, pH = 4.6, 150 mM NaCl,
1% BSA, 0.5% Nonidet P-40 (IGEPAL CA-630, Sigma, St. Louis, MO, USA), 0.1% NaN3) in duplicate for
3 days at 37 ◦C. The reaction was quenched by adding two volumes of neutralization buffer (100 mM
Tris-HCl, pH = 8.6, 150 mM NaCl, 1% BSA, 0.5 Nonidet P-40 (IGEPAL CA-630, Sigma), 0.1% NaN3).
Monoclonal anti-DQ (SPV-L3) antibodies (Cat# BNUM0200-50, Biotium, Fremont, CA, USA) (1:400
dilution in 100 mM carbonate-bicarbonate buffer, pH = 9.5) were coated onto a high binding 96-well
plate (REF# 9018, Corning), and incubated with neutralized reaction for 1–2 h at room temperature
(RT). After washing five times with 300 µL/well of wash buffer (phosphate-buffered saline (PBS),
0.05% Tween-20, pH = 7.4), 100 µL/well of Europium (Eu)-labelled streptavidin (Cat# 1244–360,
PerkinElmer, Waltham, MA, USA) (1:1000 dilution in PBS, 1% BSA, pH = 7.4) was added and incubated
for 1 h at RT. After washing 5 times again with 300 µL/well of wash buffer, DELFIA® time-resolved
fluorescence (TRF) intensity was detected using a Tecan Infinite® M1000 after adding 100 µL/well
of enhancement solution (Cat# 1244–105, PerkinElmer). Non-specific binding was removed through
extensive wash with wash buffer. Competitor peptide with Eu TRF intensity that was lower than 25%
of Bio-EBV epitope alone was considered strong binder, while peptide with 25–50% was weak binder.
In silico binding: The DQ0602 peptide binding prediction algorithm (http://tools.iedb.org/mhcii/)
was used to assess if mutated motifs derived from the mass spectroscopic readouts changed DQ0602
peptide-binding registers. Consequently, three 20 mer peptide variants derived from the X179 strain,
wild type pH1N1, and mutated motif from the vaccines were used to query the DQ0602 binding
prediction server [36]. The 20 mer peptide stretches surrounding the mutated motif (10 aa upstream
and 10 aa downstream of the mutated motif) or the homologous position in the reference strains were
constructed using custom python scripts.
2.5. Tetramer Analysis
For a few selected peptides where mutations were found to alter T cell reactivity when presented
by DQ0602 potentially, and when these could be hypothesized to explain why Pandemrix could have
been more narcolepsy triggering than Arepanrix, DQ0602 peptide tetramers were created and tested in
six narcolepsy cases (5 post Pandemrix, one recent onset) and 4 DQ0602 control cases (all vaccinated
with Pandemrix in 2009–2010) as described in Luo et al. [32].
3. Results
3.1. Characterization of Protein Content in Arepanrix and Pandemrix
Each vaccine lot was digested with trypsin and chymotrypsin and then subjected to MS
characterization, thereby ensuring high coverage of the representative protein content. Mean coverage
for the influenza proteins was 80.5% in Pandemrix versus 71.1% in Arepanrix (Supplementary Figure S1).
We observed highly similar mean global proportions of influenza (Pandemrix 60.2%; Arepanrix 59.4%),
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chicken (Pandemrix 31.7; Arepanrix 31.4%), and bovine proteins (Pandemrix 7.9%; Arepanrix 9.1%) in
these vaccines (Figure 1A). Such results are consistent, given that both vaccines are produced from the
same parent NYMC X-179A reassortant virus consisting of PR8 backbone and pH1N1 surface proteins.
Bovine proteins are likely reflecting deoxycholate solubilization, as this compound is isolated from
bovine gallbladder extracts.
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3.2. Differential Mutation Proportions among Arepanrix and Pandemrix
A comparison of mutations in Pandemrix and Arepanrix uncovered 17 significantly interesting
site-specific differences in relation to reference X-179A strain. 4 HA motifs were represented differently
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among the vaccines. Most significantly, the HA 146 (p.Asn146Asp) residue, which is close to a receptor
binding site that interacts with human respiratory epithelial cells to initiate infection, was deamidated
nearly six times more in Arepanrix (59.7%) than Pandemrix (10.7%). This mutation was by far the most
significant difference among the two vaccines (p = 4.4 × 10−6), confirming previous observations that
the difference in HA 146 was an apparent outlying mutation between Arepanrix and Pandemrix [30].
The other mutated residues in hemagglutinin included HA 314 (p.Pro314Gln, p = 5.7 × 10−4), HA 482
(p.Phe482Tyr, p = 8.4 × 10−3), and HA 420 (p.Arg420Ile, p = 4.2 × 10−2), all significantly enriched at
least 3-fold in Arepanrix (Table 3, Figure 2A).
Table 3. Significantly different mutated motifs as compared to X179A strain in six batches of Pandemrix®
and five batches of Arepanrix®.
Protein Pos
(Intial >Mut)
p-Value T−Stat (CI U ± L)
Mean Proportion%
Arepanrix Pandemrix
HA 146 (N > D) 4.40 × 10−6 10.2 (60 ± 38) 59.7 10.7
HA 314 (P > Q) 5.70 × 10−4 7.3 (55.6 ± 27) 44.2 2.9
HA 420 (R > I) 4.42 × 10−2 2.8 (45 ± 1) 24.2 1.3
HA 482 (F > Y) 8.24 × 10−3 4.3 (51.2 ± 12.6) 38.5 6.6
M1 49 (R > I) 3.90 × 10−3 4.6 (76.8 ± 23.4) 79.1 29
M1 84 (L > P) 2.24 × 10−2 −2.9 (−1.2 ± −11.6) 14.9 21.3
M1 85 (N > D) 1.78 × 10−2 −3.4 (−2.8 ± −19) 23.5 34.4
M1 91 (N > D) 1.66 × 10−2 3.1 (13.2 ± 1.8) 17.7 10.3
M1 92 (N > D) 2.61 × 10−3 4.2 (7.6 ± 2.2) 10.2 5.3
M1 99 (L > M) 2.12 × 10−2 2.8 (11 ± 1.1) 10.4 4.3
NP 11 (E > Q) 2.80 × 10−5 7.9 (11.1 ± 6.2) 10.5 1.9
NP 257 (T > A) 5.20 × 10−4 −6.8 (−4 ± −8.5) 0.3 6.5
NP 321 (N > D) 2.14 × 10−2 3.3 (41.8 ± 5.3) 29.2 5.7
NP 423 (T > R) 3.19 × 10−2 −2.9 (−0.5 ± −7.4) 0 4
NP 424 (T > I) 3.65 × 10−3 −5.1 (−3.6 ± −10.8) 0.1 7.3
NP 432 (N > D) 1.28 × 10−2 3.1 (13.6 ± 2.1) 17.2 9.3
NP 469 (E > D) 1.13 × 10−2 3.9 (12.9 ± 2.6) 11.5 3.8
NP, which is derived from PR8 and not pH1N1 sequence, also accumulated mutations that
differentiated the two vaccines. For instance, the NP 11 (p.Glu11Gln, p = 2.8 × 10−5) residue mutated
nearly 5 times more in Arepanrix (10.5%) than Pandemrix (1.9%), while deamidations were frequently
enriched in Arepanrix at NP 321 (p.Asn321Asp, p = 0.02) and NP 432 (p.Asn432Asp, p = 0.01).
It should be noted that some NP mutations occurred more frequently in Pandemrix than Arepanrix;
the most significant of these include the following residues: NP 257 (p.Thr257Ala, p = 5.2 × 10−4),
NP 423(p.Thr423Arg, p = 3.1× 10−2) and NP 424 (p.Thr424Ile, p = 3.6 × 10−3) (Table 3 and full list of
mutations per batch in Supplementary Table S6).
Matrix protein 1, also derived from PR8, was observed to have a differential accumulation of
mutations between Arepanrix and Pandemrix. The most significant differences include the residue
M1 49 (p.Arg49Ile, p = 3.9 × 10−3) as well as adjacent motifs deamidated at M1 91 (p.Asn91Asp,
p = 1.6 × 10−2), M1 92 (p.Asn92Asp, p = 2.6× 10−3) and M1 99 (p.Leu99Met, p = 2.1× 10−2), that were all
over represented in Arepanrix. Meanwhile, two adjacent motifs at M1 84 (p.Leu84Pro, p = 2.2 × 10−2)
and M1 85 deamidation (p.Asn85Asp, p = 1.7 × 10−2) were enriched in Pandemrix (Table 3).
Statistical comparison of mutation proportions revealed a general trend in increased differential
mutations across in Arepanrix compared to Pandemrix and, as shown in Figure 2. Of interest,
statistically significant (p-value < 0.05) mutations, such as HA 146, HA 314, and NP 11,
typically occurred more often in Arepanrix than Pandemrix.
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Figure 2. Mean mutation proportion in Arepanrix versus Pandemrix. (A) Each data point represents a
specific mutated amino acid. This scatterplot maps the log-transformed mean mutation proportion in
Pandemrix on the x-axis against log-transformed mean mutation proportion in Arepanrix on the y-axis.
Calculated from a two-tailed Student’s t-test; the p-value of each data point indicates how significantly
different the mutation is between vaccines. As data points are colored based on their p-value, the redder
on the gradient scale, the more significant the mutation is in regard to differentiating Pandemrix and
Arepanrix. (B) The heatmap is indicating the actual mutational proportion with the y-axis showing the
mutated positions and the x-axis showing the vaccine lots.
3.3. DQ0602 Binding of Mutated Motifs in Arepanrix and Pandemrix
We next sought to determine whether these mutated and enriched motifs (Table 3) in either
Pandemrix or Arepanrix modified their HLA binding registers and subsequently their overall propensity
to bind narcolepsy associated DQ0602 allele. A combination of in-vitro and in-silico methods was
adopted to address this question. We synthesized 15 mer peptide stretches overlapping by 4mers
using the most abundant viral proteins (HA, NA, NP, M1 & PB2) from reference strains (X179A and
wild type pH1N1) as a template. These 15 mer peptides were used to quantify DQ0602 binding
affinities relative to a known EBV derived 15 mer peptide that is a strong binder [32]. In this way,
a database of experimentally derived peptide binders from the abundant viral proteins was built. Next,
we compared the mutated motifs (Table 3) from the vaccines to the reference motifs already tested for
DQ0602 binding.
Among the mutations described in Table 3, six of the variant motifs changed the DQ0602 binding
register. First, we confirmed that the previously described HA 146 (N to D) mutation enriched in
Arepanrix changed peptide-binding register to bind strongly to DQ0602 (N allele 4.4%, D allele 53.47%).
Second, we identified five novel mutations that changed DQ0602 binding registers. NP 257 (T to A)
was enriched in Pandemrix and changed the binding register to DL[A]FLARSA (A allele 4.8%) from
the reference DL[T]FLARSA (T allele 15.7%), this change is again projected to increase the binding
affinity to DQ0602. Other mutations that modified DQ0602 binding registers are NP 423, HA 420,
MA1 49 (see Supplementary Tables S1 and S2). Considering their differential abundance in Pandemrix
versus Arepanrix and expected changes in binding register, we determined that only four mutations
i.e., HA 146, NP 423, NP 424, and NP 257, have the potential to explain differential effects of these
vaccines on narcolepsy.
3.4. Tetramer Studies of Four Mutated Motifs that Could Have Impacted Narcolepsy Risk
Our analysis projected that four Pandemrix enriched mutations (i.e., HA 146, NP 423, NP 424,
and NP 257, see Supplementary Tables S1 and S2) within the DQ0602 binding registers could influence
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narcolepsy susceptibility. We thus conducted DQ0602 tetramer screens of the mutated motifs (Table S3)
in expanded PBMCs as described previously [32] split into three conditions (i.e., stimulated with
Arepanrix, Pandemrix, or specific mutated peptide) to identify cognate mutated peptide-specific CD4+
T cells. Six narcolepsy cases (5 post Pandemrix, one recent onset) and 4 DQ0602 control cases (all
vaccinated with Pandemrix in 2009–2010) described in Luo et al. [32] were selected for this screen.
While there appeared to be sporadic reactivity to some mutated motifs, we did not observe any
significant differences in the frequencies of tetramer specific CD4 T cells in narcolepsy cases vs. controls
(supplementary Tables S4 and S5). In comparison to immunodominant motifs we identified in our
prior screens in these same patients, these epitopes [18] were considered insignificant.
4. Discussion
This study extends the Jacob et al. report [30] where only single batches of Arepanrix and
Pandemrix were analyzed and presents a detailed characterization of the mutational burden and
protein content of 5 Arepanrix and 6 Pandemrix batches. Mean coverage of the mass spectrometric
characterization of influenza proteins, while still at high 71.1% in Arepanrix and 80.5% in Pandemrix,
was slightly less than what Jacob et al. [30]. The sampled lots were actual vaccine doses used during
the 2009 pandemic influenza vaccination campaign in Northern Europe and Canada, except for
two lots that were monovalent bulks and sourced directly from GSK (see Table 1). Not surprisingly,
considering that both Arepanrix and Pandemrix were derived from NYMC X-179A [26,30], the mean
global proportions of Influenza, chicken and bovine proteins were comparable between the two
vaccines (Figure 1). This finding agrees with Jacob et al. [30], where similar global proportions were
observed. The four main influenza proteins in order of abundance were NP, HA, M1, NA, and PB2
(Table 2), which is consistent with other studie [26,30], while PB1, NS1 and nuclear export protein
(NEP) were only present at low concentrations (<1%) in both the vaccines.
We found that NA was significantly enriched three-fold in Pandemrix as compared to Arepanrix
confirming the trend identified previously in Jacob et al. [30]. In contrast, NP was underrepresented
in Pandemrix compared to Arepanrix, although this difference was not statistically significant.
This finding conflicts with the reports of Jacob et al. [30], Vaarala et al. [33] and Ahmed et al. [34],
all of which observed an overrepresentation of NP content in Pandemrix. The main limitation in
these studies mentioned earlier is however that only one representative batch of each vaccine or
the monovalent antigen bulk [30,33]. In addition, the protein content was characterized by various
techniques including western blots, PAGE gels and mass spectrometry in these studies. In this study,
we have characterized 6 different Pandemrix lots and 5 different Arepanrix lots, with the majority of
them being actual vaccine doses. Further, using both trypsin and chymotrypsin protein digests to
increased our protein coverage thus the finding may be more reliable. However, we did not perform
any enrichment before MS characterization, which may have influenced our current results.
As recently reported, we found that vaccine strains, like wild type virion infecting hosts, mutate in
culture, and this leads to divergences in vaccine viral sequences in different vaccines or across vaccine
batches. Differences may thus depend on how often the manufacturer reuses the primary NYMC
strain versus continuing to amplify isolates from their own egg cultures for future propagation. As an
example, Skowronski et al. found that H3N2 reassortant vaccine strains had mutated in key antigenic
residues, likely contributing to reduced efficacy in 2012–2013 [37]. Similarly, Jacob et al., conducting
Mass Spectrometry (MS) characterization of X-179A derived pH1N1 vaccines, 2009 Pandemrix and
2010 Arepanrix, discovering that a specific HA mutation, N146D, had accumulated in Arepanrix,
distinguishing the two antigens [30] (limitation in the Jacob et al. study was that only a representative
batch of actual Pandemrix vaccine (batch DFLSA014A) and bulk Arepanrix (batch SF1B0454Cl) was
studied and compared). Further, the Arepanrix lot was a lot that had never been used and had been
prepared one year after the pandemic (2010). In this study, we could confirm the dominance of N146D
in Arepanrix but not Pandemrix across all lots. Interestingly, this mutation conferred higher growth and
Vaccines 2020, 8, 630 10 of 13
was selected in subsequent pH1N1 strains X-181 [26]. It may thus be that the mutation accumulated in
Arepanrix but not Pandemrix because of differences in Arepanrix culture procedures.
As it was conceivable that the N146 sequence found in Pandemrix and wild type H1N1 but
not Arepanrix was essential to explain narcolepsy susceptibility, we further examined binding of
both N146 and D146 peptides on DQ0602 molecules, confirming in vitro prediction indicating that
146 binds with lower affinity to DQ0602, another factor that could contribute to different susceptibility.
Using DQ0602 tetramers for sequences; however, we found that very few T cells recognized these
peptide sequences in both narcolepsy and control subjects, making it unlikely to be of significance in
narcolepsy pathophysiology. Similar to the study of HA N146D, we also studied tetramers for NP T424I,
NP T423I, and NP T257A, three other mutations that are much more abundant in Pandemrix versus
Arepanrix (Table 1) and were predicted to bind DQ0602 with an equivalent affinity (supplementary
Table S1). In vitro binding studies indeed found that all these peptides bound DQ0602 with high
affinity. However, tetramer studies in narcolepsy and controls did not support abundance for T cells
recognizing these epitopes making it unlikely to be functionally important.
With recent results suggesting that a potential mimic of HCRTNH2 is pHA273–287, we also carefully
examined frequency and sequence variation within this segment, present in both wild type pH1N1,
X-179A and X181, but could not find any mutation or difference in frequency across vaccines, making it
unlikely composition difference at this level explain differential narcolepsy risk. It is nonetheless
interesting to note that pHA273–287 contains N at position 273 (predicted to bind DQ0602 in P1) and
that this residue is partially glycosylated [30], a modification that could make a difference in B cell
reactivity and perhaps epitope processing and presentation to T cells. A future direction would
be to profile in detail the post-translational modifications in these motifs across the two vaccines.
For instance, possible deamidation in the MHC binding pocket could alter the DQ0602 binding
register and glycosylation in or flanking the pHA273–287 or in other cases, PTMs such as N-linked
or O-linked glycosylation have also been shown to protect epitope cleavage sites, prevent efficient
antigen processing, or influence recognition by cognate T-cell receptors [38]. Glycosylation patterns
in key residues across vaccines are, therefore, also of interest in the context of DQ0602 binding and
narcolepsy susceptibility.
5. Conclusions
In summary, characterization of the mutation load of several Pandemrix and Arepanrix lots
revealed extensive differences in influenza mutation frequencies when compared across the vaccines
and also in relation to the parent vaccine strain X179A. We also did not find any single mutations
within the most likely culprit mimic sequence that may trigger autoimmunity, pHA273–287 in this study.
Future research exploring double mutations or PTMS in this region (pHA273–287) and additional
flanking regions are underway in our laboratory and could yield additional answers. Nonetheless,
as identified in this study, the vaccine composition is complex and diverse, and thus unrecognized
differences could still play a role. As an example, it is notable that a significant portion of spectrograms
in these vaccines does not map to any known protein sequence, thus our search for differences that
could be involved in narcolepsy triggering was in no way exhaustive. Beside vaccine differences, it may
also well be that difference in past or concomitant microbial exposure of the Canadian (vaccinated
with Arepanrix), and northern European population (vaccinated with Pandemrix) could be primarily
involved, for example, timing of concomitant pH1N1 infection, past H3N2 infections, or presence of
specific streptococcal A infections, as suggested by other studies [39].
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Figure S1: The percentage coverage of the main influenza viral proteins as characterized by mass spectrometry
across different vaccine lots derived from Pandemrix and Arepanrix post digestion with trypsin and chymotrypsin.
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in vitro DQ0602 binding effects, binding repertoire and tetramer results, Table S3: Peptide motifs selected for
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